Mary L Howard, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1330 Commercial St, Warsaw, MO 65355 Phone: 636-390-3173 |
Ryan Loehr, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1330 Commercial St, Warsaw, MO 65355 Phone: 660-438-7331 |
Lori Dawn Berger, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 103 W Polk St, Warsaw, MO 65355 Phone: 660-438-2207 Fax: 660-438-4304 |
Kelli Kathleen Tate, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 103 W Polk St, Warsaw, MO 65355 Phone: 660-438-2207 Fax: 660-438-4304 |
Donald Wayne Grove Jr., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1330 Commercial, Warsaw, MO 65355 Phone: 660-438-7331 Fax: 660-438-6168 |
Murphy Affolder Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 103 W Polk St, Warsaw, MO 65355 Phone: 660-438-2207 |
Dr. Bryce A Phillips Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1330 Commercial St, Warsaw, MO 65355 Phone: 660-438-7331 |
Dr. Tiffany Mary Crowell, PHARMD Pharmacist - Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist Medicare: Not Enrolled in Medicare Practice Location: 103 W Polk St, Warsaw, MO 65355 Phone: 660-438-2207 Fax: 660-438-4304 |
Kaetlyn Leigh Taunton, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 103 W Polk St, Warsaw, MO 65355 Phone: 660-438-2207 |
News Archive
A recent study conducted by a team of US-based scientists has revealed that unvaccinated individuals are 17-times more likely to be hospitalized due to severe coronavirus disease 2019 (COVID-19) compared to those vaccinated against the disease. The study is currently available on the medRxiv* preprint server.
Edifecs, Inc., the proven leader in healthcare transaction interoperability solutions, announced today it is providing a free Commercial-Off-The-Shelf (COTS) solution that is fully compliant with the new Centers for Medicare & Medicaid Services (CMS) requirements for Medicare Administrative Contractors (MACs).
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
A report by the influential Commons Select Committee on Health, criticises the drugs industry for promoting the wider use of medication in a bid to increase its profits, and says Britain is being turned into "pill for every ill" society by the multibillion-pound drugs industry, which encourages patients to take medication even for "unhappiness".
› Verified 8 days ago